Status:
COMPLETED
CompArison of PCI in NaTive Arteries Versus ByPAss Grafts In PatieNts With Prior CABG (CAPTAIN)
Lead Sponsor:
Beijing Anzhen Hospital
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
Brief Summary
Coronary atherosclerotic heart disease (CAD) has been considered the leading cause of death in both developed and developing countries. Coronary artery bypass grafting (CABG) is a major therapy of CAD...
Eligibility Criteria
Inclusion
- Patients received first percutaneous coronary intervention in native arteries or in bypass grafts after coronary artery bypass grafting
Exclusion
- Patients who missed follow-up data were excluded
Key Trial Info
Start Date :
October 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2022
Estimated Enrollment :
1491 Patients enrolled
Trial Details
Trial ID
NCT05368597
Start Date
October 1 2019
End Date
May 1 2022
Last Update
May 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100000